AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT00099320
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00099333
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 69
- Registration Number
- NCT00097500
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
- First Posted Date
- 2004-10-18
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00094328
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2004-09-29
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 179
- Registration Number
- NCT00093002
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3
Withdrawn
- Conditions
- Non-Small-Cell Lung Carcinoma
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00090675
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 249
- Registration Number
- NCT00090324
- Locations
- 🇺🇦
Research Site, Odessa, Ukraine
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: PlaceboDrug: ZD4054 10 mgDrug: ZD4054 15 mg
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 447
- Registration Number
- NCT00090363
- Locations
- 🇬🇧
Research Site, York, United Kingdom
🇫🇷Research site, Pontoise, France
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania
Phase 3
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT00090311
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
AZD5438 in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00088790
- Locations
- 🇺🇸
Research Site, New York City, New York, United States
© Copyright 2025. All Rights Reserved by MedPath